Stockscreener 앱 받기
13.13
0.15%
0.02
시간 외 거래:
13.01
-0.12
-0.91%
전일 마감가:
$13.11
열려 있는:
$13.1
하루 거래량:
1.17M
Relative Volume:
0.59
시가총액:
$789.74M
수익:
$439.00K
순이익/손실:
$-105.64M
주가수익비율:
-7.2944
EPS:
-1.8
순현금흐름:
$-60.70M
1주 성능:
+7.80%
1개월 성능:
-6.41%
6개월 성능:
-45.90%
1년 성능:
-64.30%
1일 변동 폭
$13.02
$13.48
1주일 범위
$12.42
$13.61
52주 변동 폭
$12.12
$38.42
Janux Therapeutics Inc Stock (JANX) Company Profile
명칭
Janux Therapeutics Inc
전화
(858) 751-4493
주소
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
13.13 | 788.54M | 439.00K | -105.64M | -60.70M | -1.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-09-17 | 개시 | Barclays | Overweight |
| 2025-09-10 | 개시 | Stifel | Buy |
| 2025-09-10 | 개시 | Truist | Buy |
| 2025-09-04 | 개시 | Guggenheim | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-07-11 | 개시 | Raymond James | Outperform |
| 2024-12-03 | 재확인 | BTIG Research | Buy |
| 2024-12-03 | 재확인 | H.C. Wainwright | Buy |
| 2024-11-22 | 개시 | Leerink Partners | Outperform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-09-06 | 개시 | Stifel | Buy |
| 2024-05-30 | 개시 | Scotiabank | Sector Perform |
| 2024-03-21 | 개시 | BTIG Research | Buy |
| 2024-03-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-04-06 | 개시 | Wedbush | Outperform |
| 2022-11-14 | 개시 | William Blair | Outperform |
모두보기
Janux Therapeutics Inc 주식(JANX)의 최신 뉴스
Janux Therapeutics, Inc. (JANX) Stock Analysis: Exploring a Potential 379% Upside in Biotech Innovations - DirectorsTalk Interviews
What is Janux Therapeutics Inc.’s valuation compared to sectorEarnings Overview Summary & Fast Momentum Entry Tips - mfd.ru
Breakout Watch: What is Janux Therapeutics Incs debt to equity ratioDividend Hike & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Bristol Myers Squibb Expands RNA And Cell Therapy Pipeline As Valuation Lags - Yahoo! Finance Canada
Janux Therapeutics (NASDAQ:JANX) Sets New 52-Week LowShould You Sell? - MarketBeat
Janux Therapeutics, Inc. (JANX) faces platform risk amid lack of durability data on JANX007 - MSN
(JANX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Wall Street Analysts See a 319.23% Upside in Janux Therapeutics (JANX): Can the Stock Really Move This High? - Yahoo Finance UK
Janux Therapeutics, Inc. (JANX) Faces Platform Risk Amid Lack of Durability Data on JANX007 - Insider Monkey
Analysts Bullish Ahead of Colorectal Cancer Readout for CytomX Therapeutics, Inc. (CTMX) - Yahoo Finance
Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Bristol-Myers Squibb Expands Cancer Efforts With New AI And Drug Deals - Yahoo Finance UK
Why is Janux Therapeutics Inc. stock going downPortfolio Value Report & Weekly High Conviction Trade Ideas - mfd.ru
Will BMY's Oncology Collaborations Drive Its Next Growth Phase? - The Globe and Mail
Janux Therapeutics Repeat Insider Selling Not A Positive Indicator - simplywall.st
Eikon Therapeutics targets $908 million valuation in US IPO - Yahoo Finance
Janux Therapeutics Partners With Bristol-Myers (BMY) on Solid Tumor Therapy - Yahoo Finance
Janux Therapeutics appoints William Go as new chief medical officer By Investing.com - Investing.com Nigeria
Janux Therapeutics (NASDAQ:JANX) Shares Gap DownShould You Sell? - MarketBeat
Janux Therapeutics Taps Dr. William Go as Chief Medical Officer - Contract Pharma
Janux Therapeutics appoints William Go as new chief medical officer - Investing.com
Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer - ChartMill
Bristol Myers inks licensing deal with Janux for cancer therapy - MSN
Janux Stock Is Rising Pre-Market After A New Oncology Deal With Bristol Myers Squibb - Stocktwits
Bristol-Myers Squibb: Solid Tumor Collaboration With Janux And Camzyos Expansion (BMY) - Seeking Alpha
BTIG Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $100 - 富途牛牛
JonesTrading Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $50 - 富途牛牛
A Look At Bristol Myers Squibb (BMY) Valuation After New Microsoft AI Pact And Camzyos Trial Results - Yahoo Finance
Price-Driven Insight from (JANX) for Rule-Based Strategy - Stock Traders Daily
JANX Enters Global Oncology Collaboration With BMY, Stock Rises - Finviz
Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug - ET Pharma
Janux Therapeutics Inks Global Oncology Collaboration With BMS - TipRanks
Janux Therapeutics Signs Exclusive License and Collaboration Agreement With Bristol-Myers Squibb - TradingView
Janux Therapeutics (NASDAQ:JANX) Sees Strong Trading VolumeHere's Why - MarketBeat
Janux Therapeutics Pairs With BMS on Novel Tumor-Activated Therapeutic - Contract Pharma
Key facts: Bristol Myers Squibb signs $850M deal with Janux; partners with Microsoft for AI - TradingView
BMS Tries Again With T Cell Engagers, Turning to Janux to Develop New Tumor-Activated Therapy - MedCity News
Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million - Benzinga
BMS bets on Janux’s novel solid tumour therapy through $850m deal - Yahoo Finance
Janux Therapeutics, Inc. Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop A Novel Tumor-Activated Therapeutic for Solid Tumors - marketscreener.com
Bristol Myers buys into Janux’s ‘masked’ T cell engagers - BioPharma Dive
Janux, Bristol Myers Squibb partner on tumor-activated therapy By Investing.com - Investing.com Canada
Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors - BioSpace
Janux stock rises after Bristol Myers Squibb collaboration deal By Investing.com - Investing.com UK
Janux stock rises after Bristol Myers Squibb collaboration deal - Investing.com
BMS Bets $850M on Janux’s Tumor-Activated Drugs, Deepening Cancer Investments - BioSpace
Janux Therapeutics Secures Exclusive License Agreement with Bristol Myers Squibb, Potential Earnings Up to $800 Million - Intellectia AI
Bristol Myers (BMY) Partners with Janux Therapeutics on Cancer T - GuruFocus
Janux Therapeutics Inc (JANX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.24%
0.19%
자본화:
|
볼륨(24시간):